• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

July 27, 2016
CenterWatch Staff

Embera NeuroTherapeutics, a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

In 2014, the U.S. had 1.5 million current cocaine users aged 12 or older. Despite this, no approved medications exist for the treatment of cocaine use disorder. EMB-001 is a novel candidate for the treatment of addiction based on the discoveries of Dr. Nicholas Goeders, professor and head of the Department of Pharmacology, Toxicology & Neuroscience at the Louisiana State University (LSU) Health Sciences Center, and licensed exclusively to Embera by LSU.

A patented combination of the FDA-approved drugs metyrapone and oxazepam, EMB-001 targets the stress response system as a novel approach to addressing addiction and relapse. The potential utility of EMB-001 in cocaine, nicotine and methamphetamine addiction has been demonstrated in preclinical studies, and clinical activity has been demonstrated in a pilot study in cocaine-dependent human subjects. Embera also recently announced the successful completion of a phase I study of the safety and tolerability of EMB-001.

“We are delighted to receive this positive validation and support from NIDA for EMB- 001, the leading product in clinical development for cocaine use disorder, for which there are currently no FDA-approved medications,” said Robert Linke, chief executive officer of Embera.

“We have seen encouraging results in a pilot study of EMB-001 in cocaine-dependent patients and, with this support, we are excited to continue the advancement of our lead candidate through a phase II proof-of-concept efficacy study,” said Michael Detke, M.D., Ph.D., chief medical officer of Embera.

EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by cues that contribute to the acquisition and maintenance of addiction.

EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, thereby possibly maximizing potential efficacy as well as minimizing safety and tolerability concerns. Therapies that reduce cravings and relapse and thus result in long-term abstinence and recovery would be significant contributions to the treatment of a broad range of addictions.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing